GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study

Clinica Chimica Acta

Volumn 452, Issue , 2016, Pages 10-17

  Connelly, Margery A ^a   Gruppen, Eke G ^b   Wolak Dinsmore, Justyna ^a   Matyus, Steven P ^a   Riphagen, Ineke J ^b   Shalaurova, Irina ^a   Bakker, Stephan J L ^b   Otvos, James D ^a   Dullaart, Robin P F ^b  

^a LIPOSCIENCE INC   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

GlycA; Glycoproteins; Nuclear magnetic resonance spectroscopy; Systemic inflammation; Type 2 diabetes mellitus

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; PROTEIN GLYCA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ANALYZER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SURVIVAL; VERY ELDERLY; BLOOD; DIABETES MELLITUS, TYPE 2; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RISK FACTOR; VASCULAR DISEASES;

ACUTE-PHASE PROTEINS; ADULT; AGED; BIOMARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; RISK FACTORS; VASCULAR DISEASES;

EID: 84946607215     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.11.001     Document Type: Article

References (48)

1. Otvos J.D., Shalaurova I., Wolak-Dinsmore J., et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin. Chem. 2015, 61:714-723.
2. Dungan K., Binkley P., Osei K. GlycA is a novel marker of inflammation among non-critically ill hospitalized patients with type 2 diabetes. Inflammation 2015, 38:1357-1363.
3. Ormseth M.J., Chung C.P., Oeser A.M., et al. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res. Ther. 2015, 17:117.
4. Dullaart R.P., Gruppen E.G., Connelly M.A., Lefrandt J.D. A pro-inflammatory glycoprotein biomarker is associated with lower bilirubin in metabolic syndrome. Clin. Biochem. 2015, 10.1016/j.clinbiochem.2015.06.016.
5. Dullaart R.P., Gruppen E.G., Connelly M.A., Otvos J.D., Lefrandt J.D. GlycA, a biomarker of inflammatory glycoproteins, is more closely related to the leptin/adiponectin ratio than to glucose tolerance status. Clin. Biochem. 2015, 48(12):811-814.
6. Bell J.D., Brown J.C., Nicholson J.K., Sadler P.J. Assignment of resonances for 'acute-phase' glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett. 1987, 215:311-315.
7. Gruppen E.G., Connelly M.A., Otvos J.D., Bakker S.J., Dullaart R.P. A novel protein glycan biomarker and LCAT activity in metabolic syndrome. Eur. J. Clin. Investig. 2015, 45:850-859.
8. Akinkuolie A.O., Buring J.E., Ridker P.M., Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J. Am. Heart Assoc. 2014, 3:e001221.
9. Gruppen E.G., Riphagen I.J., Connelly M.A., Otvos J.D., Bakker S.J., Dullaart R.P. GlycA, a pro-inflammatory glycoprotein biomarker, and incident cardiovascular disease: relationship with C-reactive protein and renal function. PLoS One 2015, 10:e0139057.
10. Akinkuolie A.O., Glynn R.J., Ridker P.M., Mora S. Protein glycan side-chains, rosuvastatin therapy, and incident vascular events: an analysis from the JUPITER trial. Circulation 2014, 130.
11. Akinkuolie A.O., Pradhan A.D., Buring J.E., Ridker P.M., Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2015, 35(6):1544-1550.
12. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J. Proteome Res. 2010, 9:4545-4553.
13. Chung C.P., Ormseth M.J., Oeser A., et al. A novel NMR biomarker of inflammation (GlycA) is elevated in systemic lupus erythematosus. Arthritis Rheum. 2014, 66:S719.
14. Matyus S.P., Braun P.J., Wolak-Dinsmore J., et al. NMR measurement of LDL particle number using the Vantera Clinical Analyzer. Clin. Biochem. 2014, 47:203-210.
15. Matyus S.P., Braun P.J., Wolak-Dinsmore J., et al. HDL particle number measured on the Vantera, the first clinical NMR analyzer. Clin. Biochem. 2015, 48:148-155.
16. Lambers Heerspink H.J., Brantsma A.H., de Zeeuw D., et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am. J. Epidemiol. 2008, 168:897-905.
17. Abbasi A., Corpeleijn E., Postmus D., et al. Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia 2011, 54:2463-2465.
18. Abbasi A., Corpeleijn E., Gansevoort R.T., et al. Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study. J. Clin. Endocrinol. Metab. 2013, 98:E1352-E1359.
19. Corsetti J.P., Bakker S.J., Sparks C.E., Dullaart R.P. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein. PLoS One 2012, 7.
20. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 2006, 26:847-870.
21. Smallcombe S.H.P.S., Keifer P.A. WET solvent suppression and its applications to LC NMR and high-resolution NMR spectroscopy. J. Magn. Reson. 1995, A117:295-303.
22. CLSI Document EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline 2004, Clinical and Laboratory Standards Institute, Wayne, PA USA.
23. CLSI Document EP5-A2: Evaluation of Precision Performance of Quantitative Measurements Methods; Approved Guideline-Second Edition 2004, Clinical and Laboratory Standards Institute, Wayne, PA.
24. CLSI Document EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach 2003, Clinical and Laboratory Standards Institute, Wayne, PA.
25. CLSI Document C28-A3: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline-Third Edition 2008, Clinical and Laboratory Standards Institute, Wayne, PA.
26. CLSI Document EP7-A2: Interference Testing in Clinical Chemistry; Approved Guideline-Second Edition 2007, Clinical and Laboratory Standards Institute, Wayne, PA.
27. Dijk W., Turner G., Mackiewicz A. Changes in glycosylation of acute-phase proteins in health and disease: occurrence, regulation and function. Glycoconj. J. 1994, 1:5-14.
28. Ceciliani F., Pocacqua V. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr. Protein Pept. Sci. 2007, 8:91-108.
29. Gornik O., Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis. Markers 2008, 25:267-278.
30. Dempsey E., Rudd P.M. Acute phase glycoproteins: bystanders or participants in carcinogenesis?. Ann. N. Y. Acad. Sci. 2012, 1253:122-132.
31. Kriat M., Vion-Dury J., Fayre R., et al. Variations of plasma sialic acid and N-acetylglucosamine levels in cancer, inflammatory diseases and bone marrow transplantation: a proton NMR spectroscopy study. Biochimie 1991, 73:99-104.
32. Hameed I., Masoodi S.R., Mir S.A., Nabi M., Ghazanfar K., Ganai B.A. Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World J. Diabetes 2015, 6:598-612.
33. Jin C., Henao-Mejia J., Flavell R.A. Innate immune receptors: key regulators of metabolic disease progression. Cell Metab. 2013, 17:873-882.
34. Pickup J.C., Crook M.A. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia 1998, 41:1241-1248.
35. Lontchi-Yimagou E., Sobngwi E., Matsha T.E., Kengne A.P. Diabetes mellitus and inflammation. Curr. Diab. Rep. 2013, 13:435-444.
36. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
37. Schmidt M.I., Duncan B.B., Sharrett A.R., et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649-1652.
38. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, J. Am. Med. Assoc. 2001, 286:327-334.
39. Higai K., Azuma Y., Aoki Y., Matsumoto K. Altered glycosylation of alpha1-acid glycoprotein in patients with inflammation and diabetes mellitus. Clin. Chim. Acta 2003, 329:117-125.
40. Sandstrom C.S., Ohlsson B., Melander O., Westin U., Mahadeva R., Janciauskiene S. An association between type 2 diabetes and alpha-antitrypsin deficiency. Diabet. Med. 2008, 25:1370-1373.
41. Fumeron F., Pean F., Driss F., et al. Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3years: the data from an epidemiological study on the insulin resistance syndrome (DESIR) study. Diabetes Care 2006, 29:2090-2094.
42. Shalaurova I., Connelly M.A., Garvey W.T., Otvos J.D. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab. Syndr. Relat. Disord. 2014, 12:422-429.
43. Mackey R.H., Mora S., Bertoni A.G., et al. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care 2015, 38(4):628-636.
44. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462.
45. Wang T.J., Larson M.G., Vasan R.S., et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 2011, 17:448-453.
46. Floegel A., Stefan N., Yu Z., et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013, 62:639-648.
47. Wurtz P., Tiainen M., Makinen V.P., et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care 2012, 35:1749-1756.
48. Brantsma A.H., Bakker S.J., Hillege H.L., et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005, 28:2525-2530.